Twelve‐month outcomes of patients unsuitable for prolonged DAPT presenting with an acute coronary syndrome and treated with polymer‐free biolimus A9 drug‐coated stents

• Published in: Catheterization and cardiovascular interventions 2018-12, Vol.92 (7), p.1220-1228
• Main Authors: Kinnaird, Tim, Abdul, Fairoz, Hailan, Ahmed, Sheikh, Azeem, Hinton, Jonathan, Yazji, Khaled, Elangovan, Senthil, Yousef, Adnan, Gallagher, Sean, Choudhury, Anirban, Anderson, Richard, O'Kane, Peter, Smith, David
• Format: Article
• Language: English
• Subjects: Acute Coronary Syndrome - mortality; Acute Coronary Syndrome - therapy; Acute coronary syndromes; Aged; Aged, 80 and over; Antiplatelet therapy; biolimus A9 drug‐coated stent; Cardiovascular Agents - administration & dosage; Cardiovascular Agents - adverse effects; Coatings; Coronary Artery Disease - mortality; Coronary Artery Disease - therapy; DAPT duration; Demographics; Demography; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Elution; Female; Hemorrhage - chemically induced; high‐bleeding risk; Humans; Implants; Male; Middle Aged; Percutaneous Coronary Intervention - adverse effects; Percutaneous Coronary Intervention - instrumentation; Percutaneous Coronary Intervention - mortality; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Preliminary Data; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus - administration & dosage; Sirolimus - adverse effects; Sirolimus - analogs & derivatives; Statistical analysis; Stents; Thromboembolism; Thrombosis; Time Factors; Treatment Outcome; United Kingdom; Vascular diseases
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/ccd.27722

Introduction Prolonged dual anti‐platelet therapy (DAPT) is undesirable in certain patients. The biolimus‐A9 drug‐coated stent (BA9‐DCS) has a rapid drug‐elution profile allowing shortened DAPT. Methods The demographics, procedural data, and clinical outcomes for 505 patients presenting with an ACS to three UK centres and treated with a BA9‐DCS stent (PCI‐DCS) were collected, and compared to a consecutive ACS cohort of unselected patients treated in the same period with drug‐eluting stents (PCI‐DES). Results PCI‐DCS patients were older, more often female with hypertension, chronic kidney disease, severe LV dysfunction, and peripheral vascular disease more frequent than the PCI‐DES cohort. PCI‐DCS patients had a much higher Mehran bleed risk score (21.5 ± 7.7 vs. 15.9 ± 7.7, P